153 related articles for article (PubMed ID: 38252362)
1. Assessment of resectability of pancreatic cancer using novel immersive high-performance virtual reality rendering of abdominal computed tomography and magnetic resonance imaging.
Kunz JM; Maloca P; Allemann A; Fasler D; Soysal S; Däster S; Kraljević M; Syeda G; Weixler B; Nebiker C; Ochs V; Droeser R; Walker HL; Bolli M; Müller B; Cattin P; Staubli SM
Int J Comput Assist Radiol Surg; 2024 Jan; ():. PubMed ID: 38252362
[TBL] [Abstract][Full Text] [Related]
2. Vascular involvement and resectability of pancreatic ductal adenocarcinoma on contrast-enhanced MRI: comparison with pancreatic protocol CT.
Noda Y; Kawai N; Kaga T; Ishihara T; Hyodo F; Kato H; Kambadakone AR; Matsuo M
Abdom Radiol (NY); 2022 Aug; 47(8):2835-2844. PubMed ID: 35760922
[TBL] [Abstract][Full Text] [Related]
3. Artificial intelligence for assessment of vascular involvement and tumor resectability on CT in patients with pancreatic cancer.
Bereska JI; Janssen BV; Nio CY; Kop MPM; Kazemier G; Busch OR; Struik F; Marquering HA; Stoker J; Besselink MG; Verpalen IM;
Eur Radiol Exp; 2024 Feb; 8(1):18. PubMed ID: 38342782
[TBL] [Abstract][Full Text] [Related]
4. Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot.
Pilgrim CHC; Maciejewska A; Ayres N; Ellis S; Goodwin M; Zalcberg JR; Haydon A
ANZ J Surg; 2022 Oct; 92(10):2565-2570. PubMed ID: 36054233
[TBL] [Abstract][Full Text] [Related]
5. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
6. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.
Wittel UA; Lubgan D; Ghadimi M; Belyaev O; Uhl W; Bechstein WO; Grützmann R; Hohenberger WM; Schmid A; Jacobasch L; Croner RS; Reinacher-Schick A; Hopt UT; Pirkl A; Oettle H; Fietkau R; Golcher H
BMC Cancer; 2019 Oct; 19(1):979. PubMed ID: 31640628
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance cholangiopancreatography enhanced by virtual reality as a novel tool to improve the understanding of biliary anatomy and the teaching of surgical trainees.
Staubli SM; Maloca P; Kuemmerli C; Kunz J; Dirnberger AS; Allemann A; Gehweiler J; Soysal S; Droeser R; Däster S; Hess G; Raptis D; Kollmar O; von Flüe M; Bolli M; Cattin P
Front Surg; 2022; 9():916443. PubMed ID: 36034383
[TBL] [Abstract][Full Text] [Related]
8. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
9. SCANPatient: study protocol for a multi-centre, batched, stepped wedge, comparative effectiveness, randomised clinical trial of synoptic reporting of computerised tomography (CT) scans assessing cancers of the pancreas.
Li L; Kasza J; Recasens A; Ioannou L; Greenhill E; Merrett N; Cavallucci D; Ellis S; Madgwick H; Ko HS; Chantrill L; Loveday B; Nikfarjam M; Croagh D; Yang J; Dwyer A; Zalcberg J; Pilgrim C;
Trials; 2024 Jun; 25(1):388. PubMed ID: 38886755
[TBL] [Abstract][Full Text] [Related]
10. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
11. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer.
Scheufele F; Hartmann D; Friess H
Transl Gastroenterol Hepatol; 2019; 4():32. PubMed ID: 31231699
[TBL] [Abstract][Full Text] [Related]
13. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
14. The use of virtual reality to assess the bony landmarks at the knee joint - The role of imaging modality and the assessor's experience.
Castille J; Remy S; Vermue H; Victor J
Knee; 2024 Jan; 46():41-51. PubMed ID: 38061164
[TBL] [Abstract][Full Text] [Related]
15. Immersive virtual reality as a teaching tool for neuroanatomy.
Stepan K; Zeiger J; Hanchuk S; Del Signore A; Shrivastava R; Govindaraj S; Iloreta A
Int Forum Allergy Rhinol; 2017 Oct; 7(10):1006-1013. PubMed ID: 28719062
[TBL] [Abstract][Full Text] [Related]
16. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
[TBL] [Abstract][Full Text] [Related]
17. Resectability of Pancreatic Cancer Is in the Eye of the Observer: A Multicenter, Blinded, Prospective Assessment of Interobserver Agreement on NCCN Resectability Status Criteria.
Giannone F; Capretti G; Abu Hilal M; Boggi U; Campra D; Cappelli C; Casadei R; De Luca R; Falconi M; Giannotti G; Gianotti L; Girelli R; Gollini P; Ippolito D; Limerutti G; Maganuco L; Malagnino V; Malleo G; Morone M; Mosconi C; Mrakic F; Palumbo D; Salvia R; Sgroi S; Zerbi A; Balzano G
Ann Surg Open; 2021 Sep; 2(3):e087. PubMed ID: 37635813
[TBL] [Abstract][Full Text] [Related]
18. Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma.
Kim HJ; Park MS; Lee JY; Han K; Chung YE; Choi JY; Kim MJ; Kang CM
Cancer Res Treat; 2019 Jan; 51(1):24-33. PubMed ID: 29397657
[TBL] [Abstract][Full Text] [Related]
19. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP;
HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633
[TBL] [Abstract][Full Text] [Related]
20. Preoperative CT Classification of the Resectability of Pancreatic Cancer: Interobserver Agreement.
Joo I; Lee JM; Lee ES; Son JY; Lee DH; Ahn SJ; Chang W; Lee SM; Kang HJ; Yang HK
Radiology; 2019 Nov; 293(2):343-349. PubMed ID: 31502935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
